Pancreatic Cancer: PEGylated Recombinant Human Hyaluronidase in Combo With Nab-Paclitaxel
+ Gemcitabine VS. Placebo + Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High
Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
How safe and how well tolerated is the study drug PEGPH20 compared with placebo when
used in combination with nab-paclitaxel and gemcitabine?
Basic Study Information
Purpose:Location: Cancer Center
PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan
(HA) produced by some tumors. Currently PEGPH20 is experimental and is being tested
in patients with pancreatic and lung cancers.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02715804?term=HALO-109-301&rank=1
Study Reference #: IGIP-16006
Lead Researcher (Principal Investigator)
Lead Researcher: Marcus Noel
Study Contact InformationStudy Coordinator: Kari Steinmetz
Phone: (585) 276-4447
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search